... 独木舟非船舶事故的船上事故，未引起淹溺和沉没 Canoe or kayak 独木舟的其他水上运输事故 Canoe or kayak 碳酸脱水酶抑制剂类引起的有害效应 Carbonic-anhydrase inhibitors ...
基于1个网页-相关网页
Carbonic Anhydrase Inhibitors 抑制剂 ; 碳酸酐酶抑制剂 ; 碳酸酐酶抑制药
topical carbonic anhydrase inhibitors 碳酸酐酶抑制剂
Adverse effects in therapeutic use, carbonic-anhydrase inhibitors 碳酸脱水酶抑制剂的有害效应
Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides, and other diuretics 碳酸脱水酶抑制剂、苯并噻二嗪类和其他利尿剂中毒
inhibitors of carbonic anhydrase 碳酸酐酶抑制剂
Carbonic anhydrase inhibitors (CAIs) were first used to lower intraocular pressure (IOP) in glaucoma in 1954, with the introduction of acetazolamide, methazolamide and diclofenamide were subsequently.
乙酰唑胺、醋甲唑胺、双氯非那胺等碳酸酐酶抑制剂自1954年起就被应用于青光眼的降眼压治疗。
参考来源 - 醋甲唑胺脂质体滴眼剂的研究·2,447,543篇论文数据，部分数据来源于NoteExpress
Carbonic anhydrase inhibitors (CAIs) were first used to lower intraocular pressure (IOP) in glaucoma in 1954, with the introduction of acetazolamide, methazolamide and diclofenamide were subsequently.
乙酰唑胺、醋甲唑胺、双氯非那胺等碳酸酐酶抑制剂自1954年起就被应用于青光眼的降眼压治疗。
Thus, systemic acidosis or the other side effects associated with oral carbonic anhydrase inhibitors are not expected to occur.
因此，不会出现全身酸中毒或其他与口服碳酸酐酶抑制剂有关的副作用。
应用推荐